Effect of Ketamine and Etomidate During RSI on Long Term Outcomes

Enrolling by invitationOBSERVATIONAL
Enrollment

1,756

Participants

Timeline

Start Date

April 6, 2022

Primary Completion Date

January 31, 2027

Study Completion Date

March 31, 2028

Conditions
Post-Traumatic Stress DisorderAcute Respiratory Failure
Interventions
DRUG

Ketamine

The RSI-LTO study collects long-term outcomes from the RSI trial (NCT05277896). In the RSI trial, patients in the ketamine group will be assigned to receive intravenous ketamine for induction of anesthesia during tracheal intubation. A dose of 2 mg/kg will be recommended, and the group assignment sheet will contain a nomogram providing the recommended dose for a range of patient weights (in pounds and kg). Treating clinicians will be able elect to give a lesser or greater dose of ketamine than recommended if felt to be required for optimal patient care.

DRUG

Etomidate

The RSI-LTO study collects long-term outcomes from the RSI trial (NCT05277896). In the RSI trial, patients in the etomidate group will be assigned to receive intravenous etomidate for induction of anesthesia during tracheal intubation. A dose of 0.3 mg/kg will be recommended, and the group assignment sheet will contain a nomogram providing the recommended dose for a range of patient weights (in pounds and kg). Treating clinicians will be able elect to give a lesser or greater dose of etomidate than recommended if felt to be required for optimal patient care.

Trial Locations (6)

27157

Wake Forest Baptist Medical Center, Winston-Salem

35233

University of Alabama Hospital, Birmingham

37203

Vanderbilt University Medical Center, Nashville

55415

Hennepin County Medical Center, Minneapolis

80045

University of Colorado Denver, Aurora

80204

Denver Health Medical Center, Denver

All Listed Sponsors
collaborator

Patient-Centered Outcomes Research Institute

OTHER

lead

Vanderbilt University Medical Center

OTHER